Table 1

Characteristics of the 15 patients with RA at baseline (=the time of initiation of TCZ)

Age (years), median (IQR)65.6 (58.3–79.0)
Sex (% female)13/15 (93%)
Disease duration (years), median (IQR)4 (1–13)
RF (% pos)8/15 (53%)
Anti-CCP (% pos)9/15 (60%)
Number of prior csDMARDs, median (IQR)1 (1–2)
Number of prior bDMARDs, median (IQR)1 (0–2)
Concomitant GCs8/15 (53%)
Concomitant csDMARDs4/15 (27%)
DAS28, median (IQR)5.9 (4.7–6.8)
CDAI, median (IQR)32.4 (21.2–40.6)
ESR (mm/hour), median (IQR)34 (15–69)
CRP (mg/L), median (IQR)11 (5–27)
  • anti-CCP, antibodies against citrullinated peptides; bDMARDs, biologic disease-modifying antirheumatic drugs; BL, baseline; CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; DAS28, Disease Activity Score based on 28 joint count; ESR, erythrocyte sedimentation rate; GCs, glucocorticoids; RF, rheumatoid factor; SJC, swollen joint count; TCZ, tocilizumab; TJC, tender joint count.